Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) announced the grant of inducement stock options totaling 57,310 shares to seven new employees, approved by its Compensation Committee in line with Nasdaq rules. The options include 36,310 shares at an exercise price of $14.34 per share, and 21,000 shares at $14.15. Vesting occurs over a four-year period, with 25% on the one-year anniversary and the rest monthly thereafter. Marinus focuses on innovative therapies for seizure disorders, with ongoing clinical trials for its lead product, Ganaxolone, aimed at various epilepsy-related conditions.

Positive

• Grant of 57,310 stock options as inducement to attract talent.
• Stock options have exercise prices tied to recent closing prices, enhancing alignment with shareholder interests.
• Strong focus on clinical trials for Ganaxolone, including recent positive developments in pediatric epilepsy.

Negative

• None.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to seven new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 57,310 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Of these stock option grants, 36,310 stock option grants have an exercise price of $14.34 per share, which is equal to the closing price of the Common Stock on April 23, 2021 (date of grant for such stock options) and 21,000 stock option grants have an exercise price of $14.15 per share, which is equal to the closing price of the Common Stock on May 10, 2021 (date of grant for such stock options). All of the stock options will vest and become exercisable as to 25% of the underlying shares on the one-year anniversary of the applicable employee’s start date of employment, and will vest and become exercisable as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments at the end of each month following such anniversary, subject to the applicable employee’s continued employment with Marinus on such vesting dates. The stock options were or will be granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, is conducting a Phase 2 trial in tuberous sclerosis complex and has recently disclosed top-line results from its Phase 2 proof-of-concept trial in PCDH19-related epilepsy. The company has initiated a Phase 3 trial in refractory status epilepticus. For more information visit www.marinuspharma.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005759/en/

FAQ

What is the significance of Marinus Pharmaceuticals granting stock options?

The grant of stock options aims to attract new talent, aligning employee interests with shareholders.

What are the exercise prices of the stock options granted by Marinus Pharmaceuticals?

The options have exercise prices of $14.34 and $14.15 per share, reflecting recent closing prices.

How many stock options did Marinus Pharmaceuticals grant?

Marinus Pharmaceuticals granted a total of 57,310 stock options to seven new employees.

What therapeutic area does Marinus Pharmaceuticals focus on?

Marinus Pharmaceuticals focuses on developing innovative treatments for seizure disorders.

What is Ganaxolone being developed for?

Ganaxolone is being developed for seizure disorders and is currently in multiple clinical trials.